Showing 1 - 20 results of 74 for search 'V V Kashtalap', query time: 0.07s Refine Results
  1. 1
    Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)

    Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation) by V. V. Kashtalap

    Published 2022-12-01
    Get full text
    Article
  2. 2
    Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?

    Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization? by O L Barbarash, V V Kashtalap

    Published 2019-12-01
    Get full text
    Article
  3. 3
    LIPID CONTROL IN PATIENTS AFTER MYOCARDIAL INFARCTION - AN EFFECTIVE TOOL FOR MANAGING CARDIOVASCULAR RISKS

    LIPID CONTROL IN PATIENTS AFTER MYOCARDIAL INFARCTION - AN EFFECTIVE TOOL FOR MANAGING CARDIOVASCULAR RISKS by O. L. Barbarash, V. V. Kashtalap

    Published 2017-05-01
    Get full text
    Article
  4. 4
    Management of ischemic risk events in patients with multifocal atherosclerosis and type 2 diabetes mellitus

    Management of ischemic risk events in patients with multifocal atherosclerosis and type 2 diabetes mellitus by O. L. Barbarash, V. V. Kashtalap

    Published 2020-06-01
    Get full text
    Article
  5. 5
    A patient with сoronary artery disease and multifocal atherosclerosis. How to optimize the prognosis?

    A patient with сoronary artery disease and multifocal atherosclerosis. How to optimize the prognosis? by O. L. Barbarash, V. V. Kashtalap

    Published 2018-09-01
    Get full text
    Article
  6. 6
    Risk management in patients with atrial fibrillation and comorbid conditions: potentialities of edoxaban

    Risk management in patients with atrial fibrillation and comorbid conditions: potentialities of edoxaban by O. L. Barbarash, V. V. Kashtalap

    Published 2020-11-01
    Get full text
    Article
  7. 7
    A Rational Approach to a De-Escalation of Double Antithrombotic Therapy: The Possibilities of Clopidogrel

    A Rational Approach to a De-Escalation of Double Antithrombotic Therapy: The Possibilities of Clopidogrel by V. V. Kashtalap, O. L. Barbarash

    Published 2019-10-01
    Get full text
    Article
  8. 8
    ACTUAL PROBLEMS OF ANTITOMBOTIC THERAPY IN ACUTE CORONARY SYNDROME (FOLLOWING THE MATERIAL PRESENTED AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2017)

    ACTUAL PROBLEMS OF ANTITOMBOTIC THERAPY IN ACUTE CORONARY SYNDROME (FOLLOWING THE MATERIAL PRESENTED AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2017) by V. V. Kashtalap, O. L. Barbarash

    Published 2017-11-01
    Get full text
    Article
  9. 9
    Clopidogrel as a part of double disaggregant therapy in ACS: a reasonable choice in complex clinical situations

    Clopidogrel as a part of double disaggregant therapy in ACS: a reasonable choice in complex clinical situations by V. V. Kashtalap, O. L. Barbarash

    Published 2019-04-01
    Get full text
    Article
  10. 10
    TIMELINE FOR THE DOUBLE ANTIPLATELET THERAPY. FACTS AND SUGGESTIONS

    TIMELINE FOR THE DOUBLE ANTIPLATELET THERAPY. FACTS AND SUGGESTIONS by O. L. Barbarash, V. V. Kashtalap

    Published 2016-02-01
    Get full text
    Article
  11. 11
    Dual antiplatelet therapy in patients with acute coronary syndrome. Results of actual clinical practice

    Dual antiplatelet therapy in patients with acute coronary syndrome. Results of actual clinical practice by O. L. Barbarash, V. V. Kashtalap

    Published 2018-11-01
    Get full text
    Article
  12. 12
    A PATIENT WITH ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION AND CONSERVATIVE MANAGEMENT. PHARMACOLOGICAL OPTIONS TO IMPROVE PROGNOSIS

    A PATIENT WITH ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION AND CONSERVATIVE MANAGEMENT. PHARMACOLOGICAL OPTIONS TO IMPROVE PROGNOSIS by O. L. Barbarash, V. V. Kashtalap

    Published 2017-12-01
    Get full text
    Article
  13. 13
    Modern possibilities of hypertension drug therapy. Candesartan and its place in the therapy

    Modern possibilities of hypertension drug therapy. Candesartan and its place in the therapy by O L Barbarash, V V Kashtalap

    Published 2013-12-01
    Get full text
    Article
  14. 14
    "NEW" PATHOLOGICAL CONTINUUM: A HYPOGONADISM, AN OSTEOPOROSIS AND THE CALCINATING ATHEROSCLEROSIS. GENERAL FACTORS OF FORMATION AND PROGRESSION

    "NEW" PATHOLOGICAL CONTINUUM: A HYPOGONADISM, AN OSTEOPOROSIS AND THE CALCINATING ATHEROSCLEROSIS. GENERAL FACTORS OF FORMATION AND PROGRESSION by V. V. Kashtalap, O. N. Hryachkova, O. L. Barbarash

    Published 2016-12-01
    Get full text
    Article
  15. 15
    Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events?

    Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? by O. L. Barbarash, V. V. Kashtalap, I. A. Shibanova

    Published 2020-09-01
    Get full text
    Article
  16. 16
    Patient after myocardial infarction: how to reduce the risk of recurrent ischemic events?

    Patient after myocardial infarction: how to reduce the risk of recurrent ischemic events? by O. L Barbarash, V. N Karetnikova, V. V Kashtalap

    Published 2015-06-01
    Get full text
    Article
  17. 17
    THE ROLE OF MULTIFOCAL ATHEROSCLEROSIS IN DEVELOPMENT OF UNFAVORABLE CARDIOVASCULAR OUTCOMES IN PATIENTS AFTER CORONARY BYPASS GRAFTING

    THE ROLE OF MULTIFOCAL ATHEROSCLEROSIS IN DEVELOPMENT OF UNFAVORABLE CARDIOVASCULAR OUTCOMES IN PATIENTS AFTER CORONARY BYPASS GRAFTING by L. S. Barbarash, K. S. Shafranskaya, V. V. Kashtalap, O. L. Barbarash

    Published 2016-02-01
    Get full text
    Article
  18. 18
    Myocardial fibrosis: Current aspects of the problem

    Myocardial fibrosis: Current aspects of the problem by V N Karetnikova, V V Kashtalap, S N Kosareva, O L Barbarash

    Published 2017-01-01
    Get full text
    Article
  19. 19
    Possibilities of PRECISE-DAPT Score for Risk Prediction of Ischemic and Hemorrhagic Events in ST-Elevated Myocardial Infarction (According to the Data of the Registry Study in Kemerovo)

    Possibilities of PRECISE-DAPT Score for Risk Prediction of Ischemic and Hemorrhagic Events in ST-Elevated Myocardial Infarction (According to the Data of the Registry Study in Keme... by D. Yu. Sedykh, V. V. Kashtalap, R. M. Velieva, O. L. Barbarash

    Published 2020-01-01
    Get full text
    Article
  20. 20
    Galectin-3 – prospective biomarker of risk stratification in patients with ST-segment elevation myocardial infarction

    Galectin-3 – prospective biomarker of risk stratification in patients with ST-segment elevation myocardial infarction by N. V. Fedorova, V. V. Kashtalap, O. N. Khryachkova, O. L. Barbarash

    Published 2015-12-01
    Get full text
    Article

Search Tools: